SLDB

+ Watchlist + Portfolio

Solid Biosciences Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.74
52-Week Range: $3.79 – $11.45
Market Cap: $975.75M
P/E (TTM): —
EPS (TTM): -1.76
Dividend Yield: —

Advanced Metrics

Price/Book: 2.56
PEG Ratio: —
Return on Equity: -65.50%
Return on Assets: -36.38%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 13.82
Debt/Equity: 0.05
Total Debt: $20.16M
Free Cash Flow: $-118.24M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $618.23M

SLDB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$8.09M	$0.00	$0.00	$0.00
Research & Development	$78.42M	$76.56M	$96.43M	$140.32M
Selling, General & Admin	$28.95M	$27.75M	$33.30M	$38.88M
Operating Expenses	$107.37M	$104.31M	$129.73M	$179.21M
Operating Income	-$99.27M	-$104.31M	-$129.73M	-$179.21M
EBITDA	-$96.87M	-$92.99M	-$121.90M	-$177.57M
Pretax Income	-$85.98M	-$96.02M	-$124.70M	-$174.32M
Net Income	-$85.98M	-$96.02M	-$124.70M	-$174.32M
Diluted EPS	-10.10	-4.83	-3.06	-1.99
Diluted Shares	8.51M	19.88M	40.82M	87.50M

SLDB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$155.38M	$74.02M	$80.23M	$59.90M
Receivables	$0.00	—	—	—
Current Assets	$219.64M	$129.73M	$157.30M	$205.46M
Total Assets	$260.25M	$164.94M	$188.66M	$232.54M
Current Liabilities	$22.51M	$14.52M	$30.26M	$33.47M
Total Debt	$28.55M	$26.27M	$24.18M	$21.16M
Total Liabilities	$48.59M	$38.46M	$51.42M	$52.53M
Retained Earnings	-$562.74M	-$658.75M	-$783.45M	-$957.77M
Shareholders' Equity	$211.67M	$126.48M	$137.25M	$180.01M
Working Capital	$197.13M	$115.22M	$127.05M	$171.98M

SLDB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$97.98M	-$94.18M	-$100.01M	-$156.29M
Capital Expenditure	-$3.02M	-$1.51M	-$654.00K	-$1.15M
Free Cash Flow	-$100.99M	-$95.69M	-$100.67M	-$157.44M
Depreciation & Amortisation	$2.41M	$2.58M	$2.46M	$1.64M
Stock-Based Compensation	$7.54M	$7.63M	$10.52M	$16.91M
Investing Cash Flow	$59.16M	$9.69M	-$16.09M	-$58.45M
Financing Cash Flow	$74.83M	$3.12M	$122.44M	$194.45M
Share Repurchases	—	$0.00	-$5.11M	-$1.68M
Net Change in Cash	$36.01M	-$81.37M	$6.34M	-$20.30M

SLDB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$30.91M	$32.41M	$38.86M	$38.13M	$46.14M
Selling, General & Admin	$9.14M	$9.28M	$9.20M	$11.27M	$11.17M
Operating Expenses	$40.05M	$41.69M	$48.06M	$49.40M	$57.31M
Operating Income	-$40.05M	-$41.69M	-$48.06M	-$49.40M	-$57.31M
EBITDA	-$38.81M	-$39.03M	-$47.68M	-$48.94M	-$56.34M
Pretax Income	-$39.28M	-$39.48M	-$45.78M	-$49.79M	-$56.74M
Net Income	-$39.28M	-$39.48M	-$45.78M	-$49.79M	-$56.74M
Diluted EPS	-0.59	-0.42	-0.48	—	-0.52
Diluted Shares	66.34M	94.14M	94.42M	—	109.81M

SLDB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$210.63M	$138.93M	$61.36M	$59.90M	$297.10M
Current Assets	$313.41M	$278.64M	$244.85M	$205.46M	$396.79M
Total Assets	$343.90M	$308.29M	$273.91M	$232.54M	$422.89M
Current Liabilities	$28.78M	$29.85M	$36.34M	$33.47M	$30.28M
Total Debt	$23.63M	$23.05M	$21.94M	$21.16M	$20.67M
Total Liabilities	$49.44M	$50.00M	$55.97M	$52.53M	$48.76M
Retained Earnings	-$822.73M	-$862.21M	-$907.99M	-$957.77M	-$1.01B
Shareholders' Equity	$294.46M	$258.29M	$217.95M	$180.01M	$374.13M
Working Capital	$284.63M	$248.79M	$208.51M	$171.98M	$366.50M

SLDB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$31.85M	-$37.41M	-$33.47M	-$53.55M	-$47.23M
Capital Expenditure	-$126.00K	-$377.00K	-$85.00K	-$565.00K	-$165.00K
Free Cash Flow	-$31.98M	-$37.79M	-$33.56M	-$54.12M	-$47.40M
Depreciation & Amortisation	$407.00K	$386.00K	$376.00K	$467.00K	$395.00K
Stock-Based Compensation	$3.34M	$3.15M	$3.93M	$6.50M	$5.15M
Investing Cash Flow	-$27.46M	-$32.73M	-$45.27M	$47.01M	$44.76M
Financing Cash Flow	$189.73M	-$1.60M	$1.18M	$5.14M	$239.03M
Share Repurchases	-$20.00K	-$1.66M	$0.00	$0.00	-$12.89M
Net Change in Cash	$130.41M	-$71.75M	-$77.57M	-$1.40M	$236.56M

Market Snapshot

About

Solid Biosciences Inc. is a life sciences company developing treatments for Duchenne muscular dystrophy, a genetic disorder causing muscle degeneration. The company focuses on gene therapy approaches to address the underlying genetic causes of the disease. Solid Biosciences is advancing multiple programs through clinical development to bring potential curative therapies to patients with Duchenne.